Published in J Transl Med on July 11, 2007
Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity. Radiology (2009) 1.95
Ultrasound-mediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized perfluorocarbon nanoemulsions. J Control Release (2011) 1.89
High intensity focused ultrasound in clinical tumor ablation. World J Clin Oncol (2011) 1.55
Magnetic resonance-guided focused ultrasound surgery: Part 2: A review of current and future applications. Neurosurgery (2012) 1.53
Image-guided focused ultrasound ablation of breast cancer: current status, challenges, and future directions. Eur Radiol (2008) 1.19
Phase-shift, stimuli-responsive perfluorocarbon nanodroplets for drug delivery to cancer. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2012) 1.18
High-intensity focused ultrasound treatment for advanced pancreatic cancer. Gastroenterol Res Pract (2014) 1.02
Histotripsy methods in mechanical disintegration of tissue: towards clinical applications. Int J Hyperthermia (2015) 0.99
The effect of high intensity focused ultrasound treatment on metastases in a murine melanoma model. Biochem Biophys Res Commun (2008) 0.92
Inhibition of glioma growth by microbubble activation in a subcutaneous model using low duty cycle ultrasound without significant heating. J Neurosurg (2011) 0.92
Low-pressure pulsed focused ultrasound with microbubbles promotes an anticancer immunological response. J Transl Med (2012) 0.91
Phase-shift, stimuli-responsive drug carriers for targeted delivery. Ther Deliv (2011) 0.90
Investigation of cellular and molecular responses to pulsed focused ultrasound in a mouse model. PLoS One (2011) 0.88
Enhancement of antitumor vaccine in ablated hepatocellular carcinoma by high-intensity focused ultrasound. World J Gastroenterol (2010) 0.88
Boosting high-intensity focused ultrasound-induced anti-tumor immunity using a sparse-scan strategy that can more effectively promote dendritic cell maturation. J Transl Med (2010) 0.85
M-HIFU inhibits tumor growth, suppresses STAT3 activity and enhances tumor specific immunity in a transplant tumor model of prostate cancer. PLoS One (2012) 0.84
Ultrasonic enhancement of drug penetration in solid tumors. Front Oncol (2013) 0.83
Endoscopic high-intensity focused US: technical aspects and studies in an in vivo porcine model (with video). Gastrointest Endosc (2015) 0.82
MR-guided pulsed high intensity focused ultrasound enhancement of docetaxel combined with radiotherapy for prostate cancer treatment. Phys Med Biol (2012) 0.80
An alternating focused ultrasound system for thermal therapy studies in small animals. Med Phys (2011) 0.79
CpG expedites regression of local and systemic tumors when combined with activatable nanodelivery. J Control Release (2015) 0.79
Novel delivery approaches for cancer therapeutics. J Control Release (2015) 0.79
Changes in growth factor levels after thermal ablation in a murine model of colorectal liver metastases. HPB (Oxford) (2011) 0.79
High intensity focused ultrasound treatment of small renal masses: Clinical effectiveness and technological advances. Indian J Urol (2010) 0.78
Development of a high-field MR-guided HIFU setup for thermal and mechanical ablation methods in small animals. J Ther Ultrasound (2015) 0.78
Induction of Th1Immune responses following laser ablation in a murine model of colorectal liver metastases. J Transl Med (2011) 0.78
Focused ultrasound-aided immunomodulation in glioblastoma multiforme: a therapeutic concept. J Ther Ultrasound (2016) 0.77
High intensity focused ultrasound enhances anti-tumor immunity by inhibiting the negative regulatory effect of miR-134 on CD86 in a murine melanoma model. Oncotarget (2015) 0.76
Image-guided ultrasound phased arrays are a disruptive technology for non-invasive therapy. Phys Med Biol (2016) 0.76
[High-intensity focused ultrasound (HIFU) for tumor pain relief in inoperable pancreatic cancer : Evaluation with the pain sensation scale (SES)]. Schmerz (2017) 0.76
Low-Intensity Focused Ultrasound Induces Reversal of Tumor-Induced T Cell Tolerance and Prevents Immune Escape. J Immunol (2016) 0.76
Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. Cancer Immunol Immunother (2016) 0.76
High-intensity focused ultrasound (HIFU) for pancreatic carcinoma: evaluation of feasibility, reduction of tumour volume and pain intensity. Eur Radiol (2016) 0.76
Comparison of the synergistic effect of lipid nanobubbles and SonoVue microbubbles for high intensity focused ultrasound thermal ablation of tumors. PeerJ (2016) 0.75
Endoscopic ultrasound-guided inoculation of transmissible venereal tumor in the colon: A large animal model for colon neoplasia. Endosc Ultrasound (2016) 0.75
Emerging Applications of Therapeutic Ultrasound in Neuro-oncology: Moving Beyond Tumor Ablation. Neurosurgery (2016) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med (1992) 22.13
Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 14.94
The danger model: a renewed sense of self. Science (2002) 13.85
Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med (2000) 5.62
Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol (2004) 5.31
High-intensity focused ultrasound in the treatment of solid tumours. Nat Rev Cancer (2005) 4.57
Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol (2005) 4.18
Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer (2004) 3.76
Dendritic cell subtypes in mouse lymphoid organs: cross-correlation of surface markers, changes with incubation, and differences among thymus, spleen, and lymph nodes. J Immunol (1997) 3.71
Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia. Int J Hyperthermia (2003) 3.49
Cancer vaccines: between the idea and the reality. Nat Rev Immunol (2003) 3.24
Heat-shock proteins as activators of the innate immune system. Trends Immunol (2002) 2.96
Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res (2006) 2.37
Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol (2004) 2.11
Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci U S A (2000) 2.10
Genomic DNA released by dying cells induces the maturation of APCs. J Immunol (2001) 2.03
Extracorporeal focused ultrasound surgery for treatment of human solid carcinomas: early Chinese clinical experience. Ultrasound Med Biol (2004) 2.00
TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med (2000) 1.90
Chromatin and cell death. Biochim Biophys Acta (2004) 1.52
Hyperecho in ultrasound images of HIFU therapy: involvement of cavitation. Ultrasound Med Biol (2005) 1.36
Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation. Ultrasound Med Biol (2004) 1.31
Extracellular ATP and TNF-alpha synergize in the activation and maturation of human dendritic cells. J Immunol (2000) 1.31
Potential role of pulsed-high intensity focused ultrasound in gene therapy. Future Oncol (2006) 1.29
Retracted Immunotherapeutic potential of B7-DC (PD-L2) cross-linking antibody in conferring antitumor immunity. Cancer Res (2004) 1.26
Uric acid promotes tumor immune rejection. Cancer Res (2004) 1.26
Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res (2001) 1.24
Inertial cavitation dose and hemolysis produced in vitro with or without Optison. Ultrasound Med Biol (2003) 1.21
S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology (1993) 1.19
Measurement of high intensity focused ultrasound fields by a fiber optic probe hydrophone. J Acoust Soc Am (2006) 1.18
High-intensity focused ultrasound in patients with late-stage pancreatic carcinoma. Chin Med J (Engl) (2002) 1.16
CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res (2000) 1.15
The intensity dependence of lesion position shift during focused ultrasound surgery. Ultrasound Med Biol (2000) 1.14
Cavitation-enhanced ultrasound thermal therapy by combined low- and high-frequency ultrasound exposure. Ultrasound Med Biol (2006) 1.09
Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs. Biochem Biophys Res Commun (2005) 1.07
High intensity focused ultrasound for the treatment of tumors. Echocardiography (2001) 1.06
Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer (2001) 1.05
Effects of high-intensity focused ultrasound in the treatment of experimental neuroblastoma. J Pediatr Surg (1992) 1.03
Expression of tumor antigens and heat-shock protein 70 in breast cancer cells after high-intensity focused ultrasound ablation. Ann Surg Oncol (2006) 1.01
Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol (1997) 1.01
Combination of thermal and cavitation effects to generate deep lesions with an endocavitary applicator using a plane transducer: ex vivo studies. Ultrasound Med Biol (2004) 1.01
The effect of surface agitation on ultrasound-mediated gene transfer in vitro. J Acoust Soc Am (2004) 0.94
Langerhans cells and prognosis in patients with gastric carcinoma. Cancer (1987) 0.94
Immunomodulation in choroidal melanoma: reversal of inverted CD4/CD8 ratios following treatment with ultrasonic hyperthermia. Biotechnol Ther (1994) 0.93
Influence of drug-induced apoptotic death on processing and presentation of tumor antigens by dendritic cells. Int J Cancer (2003) 0.90
Extracellular uridine nucleotides initiate cytokine production by murine dendritic cells. Cell Immunol (1999) 0.90
Expression of heat shock proteins in human hepatocellular carcinoma after radiofrequency ablation in an animal model. Oncol Rep (2004) 0.87
MART-1 adenovirus-transduced dendritic cell immunization in a murine model of metastatic central nervous system tumor. J Neurooncol (2003) 0.81
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol (2005) 2.31
A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med (2005) 2.26
Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol (2007) 2.26
Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. J Virol (2006) 2.16
Maximizing the retention of antigen specific lymphocyte function after cryopreservation. J Immunol Methods (2005) 2.16
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood (2008) 2.13
New variants of porcine epidemic diarrhea virus, China, 2011. Emerg Infect Dis (2012) 2.02
The role of stress waves and cavitation in stone comminution in shock wave lithotripsy. Ultrasound Med Biol (2002) 1.92
Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol (2005) 1.88
Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther (2005) 1.87
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2008) 1.83
Use of tablet personal computers for sensitive patient-reported information. J Support Oncol (2009) 1.73
An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest (2010) 1.71
Electronic patient-reported data capture as a foundation of rapid learning cancer care. Med Care (2010) 1.67
Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported data. Health Serv Res (2008) 1.65
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother (2009) 1.63
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol (2008) 1.60
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. J Transl Med (2012) 1.59
The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry (2009) 1.58
Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res (2011) 1.58
Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. J Immunother (2004) 1.40
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother (2008) 1.39
HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. Cancer Res (2011) 1.38
Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells. Immunity (2004) 1.37
Innovations in shock wave lithotripsy technology: updates in experimental studies. J Urol (2004) 1.36
Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. Mol Ther (2009) 1.34
Dendritic cell-based immunotherapy. Int Rev Immunol (2006) 1.30
The effect of treatment strategy on stone comminution efficiency in shock wave lithotripsy. J Urol (2004) 1.29
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys (2007) 1.28
Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys (2005) 1.28
Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res (2005) 1.28
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst (2010) 1.26
Interaction of lithotripter shockwaves with single inertial cavitation bubbles. J Fluid Mech (2007) 1.24
Toward protecting the safety of participants in clinical trials. Control Clin Trials (2003) 1.23
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol (2006) 1.21
Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism. Breast Cancer Res Treat (2012) 1.21
Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg (2007) 1.19
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. Breast Cancer Res (2013) 1.18
Measurement of high intensity focused ultrasound fields by a fiber optic probe hydrophone. J Acoust Soc Am (2006) 1.18
Minimization of heatwave morbidity and mortality. Am J Prev Med (2013) 1.16
Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin Cancer Res (2011) 1.15
Accelerated partial breast irradiation after conservative surgery for breast cancer. Ann Surg (2004) 1.15
Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. Mol Cancer Ther (2008) 1.13
Increasing vaccine potency through exosome antigen targeting. Vaccine (2011) 1.13
Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Ther (2007) 1.12
Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell (2006) 1.12
Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J Transl Med (2007) 1.11
BegoStone--a new stone phantom for shock wave lithotripsy research. J Acoust Soc Am (2002) 1.11
Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.10
Longitudinal patterns of chemotherapy use in metastatic colorectal cancer. J Oncol Pract (2009) 1.10
Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis. J Am Coll Surg (2007) 1.09
Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res (2012) 1.09
Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. Hum Gene Ther (2012) 1.08
Progressive increase of lithotripter output produces better in-vivo stone comminution. J Endourol (2006) 1.08
CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin Biol Ther (2007) 1.07
Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs. Biochem Biophys Res Commun (2005) 1.07
Dynamics of tandem bubble interaction in a microfluidic channel. J Acoust Soc Am (2011) 1.06
CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer. BioDrugs (2009) 1.06
High definition laparoscopy: objective assessment of performance characteristics and comparison with standard laparoscopy. J Endourol (2009) 1.06
A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Oncologist (2011) 1.05
Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma cross talk with NF-kappaB and C/EBP. Blood (2007) 1.03
Automated single-cell motility analysis on a chip using lensfree microscopy. Sci Rep (2014) 1.03